Debjit Chattopadhyay
Stock Analyst at Guggenheim
(3.04)
# 1,406
Out of 4,761 analysts
77
Total ratings
44.12%
Success rate
1.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RZLT Rezolute | Reiterates: Buy | n/a | $4.53 | - | 2 | Feb 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Reiterates: Buy | n/a | $16.63 | - | 5 | Feb 10, 2025 | |
| DYN Dyne Therapeutics | Reiterates: Buy | n/a | $14.01 | - | 4 | Jan 24, 2025 | |
| QURE uniQure | Reiterates: Buy | n/a | $12.84 | - | 5 | Dec 11, 2024 | |
| PRME Prime Medicine | Reiterates: Buy | $18 | $2.97 | +507.08% | 3 | Dec 3, 2024 | |
| BNTC Benitec Biopharma | Reiterates: Buy | $17 | $11.30 | +50.44% | 2 | Dec 3, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $13 → $15 | $9.19 | +63.22% | 2 | Nov 7, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $70 → $65 | $32.32 | +101.11% | 3 | Oct 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $558 | $484.24 | +15.23% | 7 | Aug 2, 2024 | |
| CRSP CRISPR Therapeutics AG | Assumes: Neutral | n/a | $47.91 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $5.93 | +220.40% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.22 | +421.33% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $175 | $187.86 | -6.85% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $18.57 | +61.55% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $40 | $46.13 | -13.29% | 1 | Nov 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $110 | $68.25 | +61.17% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $2.17 | +1,236.41% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $0.52 | +1,996.04% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $50 | $42.59 | +17.40% | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $250.59 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $130 | $30.43 | +327.21% | 1 | Jan 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.61 | +1,639.13% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $170 | $12.17 | +1,296.88% | 1 | Oct 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $11.13 | +79.69% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $221 | $106.28 | +107.94% | 4 | Aug 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $26.74 | +359.99% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $14.39 | +275.26% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.96 | +2,961.22% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $35.22 | - | 3 | Jun 26, 2017 |
Rezolute
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $4.53
Upside: -
Centessa Pharmaceuticals
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $16.63
Upside: -
Dyne Therapeutics
Jan 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $14.01
Upside: -
uniQure
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $12.84
Upside: -
Prime Medicine
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $2.97
Upside: +507.08%
Benitec Biopharma
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $11.30
Upside: +50.44%
Amicus Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $9.19
Upside: +63.22%
Ionis Pharmaceuticals
Oct 9, 2024
Maintains: Buy
Price Target: $70 → $65
Current: $32.32
Upside: +101.11%
Vertex Pharmaceuticals
Aug 2, 2024
Maintains: Buy
Price Target: $450 → $558
Current: $484.24
Upside: +15.23%
CRISPR Therapeutics AG
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $47.91
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $5.93
Upside: +220.40%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $4.22
Upside: +421.33%
Feb 27, 2024
Maintains: Buy
Price Target: $130 → $175
Current: $187.86
Upside: -6.85%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $18.57
Upside: +61.55%
Nov 21, 2023
Assumes: Buy
Price Target: $40
Current: $46.13
Upside: -13.29%
Sep 13, 2023
Reiterates: Buy
Price Target: $110
Current: $68.25
Upside: +61.17%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $2.17
Upside: +1,236.41%
Nov 11, 2022
Maintains: Buy
Price Target: $13 → $11
Current: $0.52
Upside: +1,996.04%
Oct 13, 2022
Upgrades: Buy
Price Target: $50
Current: $42.59
Upside: +17.40%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $250.59
Upside: -
Jan 5, 2022
Initiates: Buy
Price Target: $130
Current: $30.43
Upside: +327.21%
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $1.61
Upside: +1,639.13%
Oct 5, 2021
Initiates: Buy
Price Target: $170
Current: $12.17
Upside: +1,296.88%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $11.13
Upside: +79.69%
Aug 31, 2020
Maintains: Buy
Price Target: $260 → $221
Current: $106.28
Upside: +107.94%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $26.74
Upside: +359.99%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $14.39
Upside: +275.26%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.96
Upside: +2,961.22%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $35.22
Upside: -